Neuronetics EVP granted 210,000 RSUs

Neuronetics, Inc. reported that executive vice president, chief legal officer and corporate secretary William Andrew Macan acquired 210,000 restricted stock units (RSUs) of common stock as an equity award.

Rhea-AI Filing Summary

Neuronetics, Inc. reported that executive vice president, chief legal officer and corporate secretary William Andrew Macan acquired 210,000 restricted stock units (RSUs) of common stock as an equity award. Each RSU represents the right to receive one Neuronetics common share.

The RSU award vests in three equal annual installments beginning on February 23, 2027, subject to Mr. Macan’s continuous service through each vesting date. Following this grant, he directly holds 883,561 shares of Neuronetics common stock. This is a non-cash, stock-based compensation grant rather than an open‑market purchase.

Insider Trade Summary

Grant/Award: 210,000 shares

Grant/Award 1 txn

Insider MACAN WILLIAM ANDREW

Role EVP, CLO and CS

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	210,000	$0.00	$0.00

Holdings After Transaction: Common Stock — 883,561 shares (Direct)

Footnotes (2)

1. F1. Represents a restricted stock unit ("RSU") award that vests in three equal annual installments beginning on February 23, 2027, in each case subject to continuous service of the Reporting Person through such date.
2. F2. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Neuronetics (STIM) report for William Andrew Macan?

Neuronetics reported that executive William Andrew Macan received an equity award of 210,000 restricted stock units. These RSUs are a form of stock-based compensation, not an open-market share purchase, and will convert into common shares only as they vest over time.

How many RSUs did Neuronetics (STIM) grant to its EVP, CLO and CS?

Neuronetics granted 210,000 restricted stock units to its EVP, CLO and CS, William Andrew Macan. Each RSU represents a contingent right to receive one share of Neuronetics common stock, effectively tying part of his compensation to the company’s future performance and continued service.

What is the vesting schedule for the 210,000 RSUs at Neuronetics (STIM)?

The 210,000 RSUs vest in three equal annual installments beginning on February 23, 2027. Each installment vests only if William Andrew Macan remains in continuous service through the applicable date, aligning the award with multi‑year retention and performance horizons.

What does each Neuronetics (STIM) RSU granted to William Andrew Macan represent?

Each restricted stock unit granted to William Andrew Macan represents a contingent right to receive one share of Neuronetics common stock. The units do not become actual shares until they vest, making this award a form of deferred equity-based compensation subject to service conditions.

How many Neuronetics (STIM) shares does William Andrew Macan own after this RSU grant?

After the reported RSU grant, William Andrew Macan directly owns 883,561 shares of Neuronetics common stock. This figure reflects his beneficial ownership following the award and helps investors gauge the scale of his equity exposure relative to the company’s overall share count.

Is the Neuronetics (STIM) RSU grant to William Andrew Macan a stock purchase?

No, the RSU grant is not a stock purchase; it is classified as a grant, award or other acquisition. Macan did not pay cash for these 210,000 units, which instead vest into common shares over time if service-based conditions are satisfied.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/25/2026 - 04:30 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MACAN WILLIAM ANDREW

(Last) (First) (Middle)

C/O NEURONETICS, INC.

3222 PHOENIXVILLE PIKE

(Street)

MALVERN PA 19355

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Neuronetics, Inc. [ STIM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, CLO and CS

3. Date of Earliest Transaction (Month/Day/Year)
02/23/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/23/2026		A		210,000(1)	A	$0(2)	883,561	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a restricted stock unit ("RSU") award that vests in three equal annual installments beginning on February 23, 2027, in each case subject to continuous service of the Reporting Person through such date.

2. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

	/s/ Patrick Devine, as Attorney-in-Fact	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.